scholarly journals SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial

2019 ◽  
Vol 30 ◽  
pp. v748 ◽  
Author(s):  
Y. Metaxas ◽  
M. Frueh ◽  
E.I. Eboulet ◽  
F. Grosso ◽  
M. Pless ◽  
...  
Keyword(s):  
Phase Ii ◽  
Malignant Pleural Mesothelioma ◽  
Palliative Chemotherapy ◽  
Phase Ii Trial ◽  
Pleural Mesothelioma ◽  
Third Line

A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma

Lung Cancer ◽  
2020 ◽  
Vol 140 ◽  
pp. 87-92 ◽  
Author(s):  
Wei-Sen Lam ◽  
Jenette Creaney ◽  
Fred K. Chen ◽  
Wee Loong Chin ◽  
Sanjeevan Muruganandan ◽  
...  
Keyword(s):  
Phase Ii ◽  
Malignant Pleural Mesothelioma ◽  
Phase Ii Trial ◽  
Pleural Mesothelioma ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

221 A randomized phase II trial of pegylated arginine deaminase (ADI-PEG 20) in patients with malignant pleural mesothelioma

Lung Cancer ◽  
2006 ◽  
Vol 54 ◽  
pp. S54 ◽  
Author(s):  
P.W. Szlosarek ◽  
D.A. Fennell ◽  
R.M. Rudd ◽  
M. Lind ◽  
M. Ranson ◽  
...  
Keyword(s):  
Phase Ii ◽  
Malignant Pleural Mesothelioma ◽  
Phase Ii Trial ◽  
Pleural Mesothelioma ◽  
Randomized Phase Ii
Sign in / Sign up

Export Citation Format

Share Document